NBIS · Financing and delivery risk
The contribution of business growth to per-share value depends on financing costs, dilution and delivery progress.
H1 statements disclose $37.49bn remaining performance obligations, but only 36% is expected within 24 months to June 2028. This is not 2027 revenue or cash available to shareholders. A September 8 Palantir partnership adds a distribution route after integration, but its announcement gives no contracted revenue amount.
Major downside risks:New debt, pre-funded warrants, share issuance and GPU replacement can absorb business growth. Customer prepayments explain most H1 operating cash and cannot be treated as recurring free cash.
Follow-up review points:Next quarterly filing and every financing 6-K: revenue-producing capacity, capex, unrestricted cash, ATM issuance and conversion terms. Monitor commissioned capacity and revenue contribution, capital expenditure and cash consumption, actual ATM issuance, and convertible conversion or cash settlement. These are future operating and capital-structure outcomes.
Assumptions, capital structure and sources
Working-capital and funding test, not P/E: with a $2bn minimum cash buffer, cumulative July 2026–December 2027 OCF/capex assumptions of $12/30bn, $22/40bn and $34/50bn imply additional funding needs of $5.50bn, $5.50bn and $3.50bn before new financing. These are researcher stresses, not management guidance or secured funding.
The funding scenario assumes full drawdown of the July $775m facility and uses August estimated net proceeds of $5,680m. Added to June cash, this gives $14,497.1m before subsequent operating/investing flows; it is not reported cash available today. The reviewed H1 note confirms the facility agreement, not full drawdown. The $800m debt exchange adds shares, not cash. Restricted cash, pre-funded warrants and previously raised NVIDIA cash cannot be added twice. Both June notes have100m assumed remaining principal after exchange. Contractual accrued principal at December31,2027 is112.269399m +109.584153m; coupon is separate. This does not resolve all convertible claims.
- Actual Class A + B common shares
- 271.855218 million · 2026-06-30 Source ↗
- Pre-funded warrant shares, additional
- 21.065936 million · 2026-06-30 Source ↗
- Unrestricted cash
- $8,042.1 million · 2026-06-30 Source ↗
- Debt carrying value
- $8,545.7 million · 2026-06-30 Source ↗
- August new notes / exchanged shares
- $5,750 million / approximately 15.8 million shares · 2026-08-24 Source ↗
- Five-year Class A issuance authorization; excludes Class C; not shares issued
- ≤20% · 2026-08-26 Source ↗
Evidence and model limitations:Reviewed H1 statements disclose 12,729,493 ATM shares sold through June 30. August closing documents disclose approximately 15.8m shares under debt-exchange agreements, but do not provide a precise consolidated share count after all subsequent transactions. The September Palantir release does not quantify contracted revenue. The June 2029/2031 contracts support principal accrual, while the H1 maturity table differs by $12.5m for each original tranche without explaining the presentation. This page presents funding stress scenarios, not an NBIS per-share target. Future conversion timing, settlement choices and option time value remain modeling assumptions.
- Nebius H1 2026 financial statements ↗ · 2026-08-12
- Q2 2026 SEC financial report ↗ · 2026-08-12
- Nebius Q2 2026 shareholder letter ↗ · 2026-08-12
- Nebius August 2026 note pricing ↗ · 2026-08-19
- Nebius August 2026 note closing ↗ · 2026-08-24
- Nebius March 2026 note closing ↗ · 2026-03-20
- Nebius September 2025 note pricing ↗ · 2025-09-10
- Nebius June 2025 note terms ↗ · 2025-06-02
- jun29-indenture ↗ · 2025-06-02
- jun-close ↗ · 2025-06-05
- jun31-indenture ↗ · 2025-06-02
- jun-subscription ↗ · 2025-06-02
- Nebius AGM results ↗ · 2026-08-26
- Palantir and Nebius sovereign AI partnership ↗ · 2026-09-08